Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Thorvardur Ragnar Halfdanarson"'
Autor:
Tucker Coston, Himil Mahadevia, Marie M. Plante, Joseph M. Accurso, Akash Sharma, Geoffrey Johnson, Jonathan Ben Ashman, Ayse T. Kendi, Mohamad B. Sonbol, Timothy J. Hobday, Thorvardur Ragnar Halfdanarson, Jason S. Starr
Publikováno v:
Journal of Clinical Oncology. 41:641-641
641 Background: Tumors of neuroendocrine origin are a rare, heterogenous group of neoplasms. Neuroendocrine neoplasms (NENs) are categorized by site of origin, differentiation status, and by grade (Ki-67 expression and/or mitotic rate), with prognost
Autor:
Thorvardur Ragnar Halfdanarson, Jaume Capdevila, Daniel M. Halperin, Ken Herrmann, Grace Kong, Simone Leyden, Josh Mailman, Diane Reidy-Lagunes, Rajaventhan Srirajaskanthan, Máté Erdö, Amanda Rotger, Thomas Thevenet
Publikováno v:
Journal of Clinical Oncology. 41:TPS660-TPS660
TPS660 Background: Deeper comprehension of gastroenteropancreatic neuroendocrine tumor (GEP-NET) characteristics has led to development of therapeutic interventions such as targeted radionuclide therapies (TRT). In the prospective, randomized, contro
Autor:
Bahar Saberzadeh Ardestani, Jeremy Clifton Jones, Joleen M. Hubbard, Robert R. McWilliams, Thorvardur Ragnar Halfdanarson, Qian Shi, Bassam Bassam Sonbol, Jonathan Ticku, Zhaohui Jin, Frank A. Sinicrope
Publikováno v:
Journal of Clinical Oncology. 41:57-57
57 Background: Metastatic colorectal cancer (mCRC) with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) show frequent and durable responses to programmed cell death -1 (PD-1) blockade. While the majority of these tumor
Autor:
Aman Chauhan, Susan M. Christner, Jan Hendrik Beumer, Charles Kunos, Aman Khurana, Riham El Khouli, Heidi Weiss, Donglin Yan, Heloisa P. Soares, Thorvardur Ragnar Halfdanarson, Daneng Li, William Edgar Carson, Mark B Evers, Percy Ivy, Elise C. Kohn, Larry Rubinstein, Susanne M. Arnold, Jill Kolesar, Lowell Brian Anthony, Bhavana Konda
Publikováno v:
Journal of Clinical Oncology. 41:648-648
648 Background: Radiation is a potent inducer of DNA double-strand breaks, and ribonucleotide reductase (RNR) is the rate-limiting enzyme for conversion of ribonucleoside diphosphate to deoxyribonucleotide diphosphate, and thus repair of DNA in this
Autor:
Patrick Walsh McGarrah, Shruthi Naik, Thorvardur Ragnar Halfdanarson, Konstantinos Leventakos, Kah Whye Peng, Stephen J. Russell, Alex A. Adjei, Julian R. Molina
Publikováno v:
Journal of Clinical Oncology. 41:TPS657-TPS657
TPS657 Background: Poorly differentiated neuroendocrine carcinoma (NEC) is an aggressive malignancy comprising both pulmonary and extrapulmonary primary sites. NEC includes both small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (L
Autor:
Sri Harsha Tella, Anuhya Kommalapati, Aakash Desai, Patrick Walsh McGarrah, Timothy J. Hobday, Thorvardur Ragnar Halfdanarson
Publikováno v:
Journal of Clinical Oncology. 40:150-150
150 Background: Pancreatic neuroendocrine tumors (pNETs) comprise less than 5% of all pancreatic tumors and 7% of all neuroendocrine tumors (NETs). There has been considerable progress in understanding the biology of pNETs and numerous therapeutic op
Autor:
Jennifer Rachel Eads, Paul J. Catalano, George A. Fisher, Daniel Rubin, Andrei Iagaru, David S. Klimstra, Bhavana Konda, Myron S. Kwong, Jennifer A. Chan, Ana De Jesus-Acosta, Thorvardur Ragnar Halfdanarson, Walid Labib Shaib, Heloisa P. Soares, Sung Chul Hong, Terence Z. Wong, Peter J. O'Dwyer
Publikováno v:
Journal of Clinical Oncology. 40:4020-4020
4020 Background: High grade (G3) GEPNENs are a rare and heterogeneous disease entity for which there is little prospective treatment data. EP chemotherapy is the treatment standard but this may not be appropriate for all G3 GEPNEN pts. CAPTEM has dem
Autor:
Aakash Desai, Daniel Walden, Thorvardur Ragnar Halfdanarson, Steven R Alberts, Robert R. McWilliams, Amit Mahipal, Daniel H. Ahn, Hani M. Babiker, Sri Harsha Tella, Patrick Walsh McGarrah, Sani Haider Kizilbash, Alex A. Adjei, Tanios S. Bekaii-Saab, Wen Wee Ma
Publikováno v:
Journal of Clinical Oncology. 40:4130-4130
4130 Background: KRAS is mutationally activated in over 90% of pancreatic ductal adenocarcinoma (PDAC). Compared to pts with KRAS mutation, KRAS wild-type (wt) PDAC seem to have better response to therapy and may harbor potentially actionable molecul
Publikováno v:
Journal of Clinical Oncology. 40:e15118-e15118
e15118 Background: Melanoma, non-small cell lung cancer (NSCLC), colorectal adenocarcinoma and thyroid tumors frequently harbor BRAF mutations and are tumor types eligible for treatment with FDA-approved BRAF inhibitors. Although there are many ongoi
Autor:
Patrick Walsh McGarrah, Jennifer Gile, Alex John Liu, Aaron Scott Mansfield, Konstantinos Leventakos, Aakash Desai, Sri Harsha Tella, Bassam Bassam Sonbol, Jason S. Starr, Timothy J. Hobday, Thorvardur Ragnar Halfdanarson
Publikováno v:
Journal of Clinical Oncology. 40:512-512
512 Background: The role of immune checkpoint inhibitors (ICIs) in the treatment of extrapulmonary neuroendocrine carcinoma (EP-NEC) has yet to be established. While objective responses have been observed, it is still unknown which patients are likel